PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

The agent's unique dual mode of action, which has both anti-catabolic and pro-anabolic activity, directly impacts two of the principle pathophysiological hallmarks of cachexia and has been shown to have beneficial effects upon both cachexia and age-related sarcopenia in vivo.

http://eon.businesswire.com/news/eon/20130304005007/en/PsiOxus-Therapeutics-Completes-Patient-Enrollment-Phase-II